Tempus AI

Tempus is a technology company making precision medicine a reality through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of de-identified multimodal data and an intelligent operating system that makes that data accessible and actionable, Tempus connects AI, diagnostics and clinical workflows to deliver more personalized patient care and accelerate the discovery, development and delivery of better medicines. By continuously transforming data into insights, we are building a learning healthcare ecosystem in which every patient can benefit from the treatment and experiences of those who came before. Learn more: https://tempus.co/4knQbvA

This #BreastCancerAwarenessMonth, we recognize the millions of patients, families, and care teams navigating the complexities of breast cancer. Because no two journeys are the same, timely genomic insights are critical for guiding targeted therapies. Tempus xF+ delivers broad-panel liquid biopsy profiling from a single blood draw to detect ESR1 and other actionable alterations at progression or when tissue is limited. Now, that same sample provides rapid pharmacogenomic (PGx) insights for DPYD and UGT1A1 in just ~3–5 days—helping evaluate toxicity risks and guide dosing without needing an extra draw. Learn more about how xF+ supports personalized care decisions: https://tempus.co/3VZftWX

We're onsite at AMCP Nexus sharing how real-world evidence can be leveraged to advance managed care pharmacy practice. During tomorrow's live session, Emilie Scherrer will expand on findings from the abstract presentation "Validation of a composite mortality variable among patients with integrated electronic health records in a large multimodal database." These findings suggest that the composite mortality variable is a reliable endpoint for real-world evidence analyses. Learn more: https://lnkd.in/egqk9tQ3

Attend tomorrow's live session at Research Revolution to hear from industry experts on how AI, operational redesign, and smarter ways of working are enabling just-in-time trial execution. Panelists Karla Polk, Catherine Gregor, Jill Johnston, and Jan Ballard will discuss what tools are improving speed and predictability, including Tempus Next, designed to accelerate clinical trial enrollment with AI-enabled pre-screening, integrated workflows and performance tracking. Learn more: https://tempus.co/3WNv7Vu #ClinicalTrials #TempusNext

Our xR assay has received certification under the European Union’s In Vitro Diagnostic Regulation (IVDR) as a Class C in vitro diagnostic device. xR detects gene rearrangements and specific splice variants in solid tumor tissue to support clinical management. This achievement furthers our work to expand access to our advanced RNA sequencing tools for healthcare providers, biopharma partners and cancer patients. Read on: https://tempus.co/4smWpOg

Our team is on-site at #ESMO26 sharing new product offerings designed to advance drug discovery and development. Visit us at Booths #1068 & 1069 to explore how our proprietary foundation models enable rapid AI application development and meaningful insights across the end-to-end drug development lifecycle, from discovery to clinical development and commercialization. Learn more about our foundation models: https://tempus.co/4ih8Tm8

Today we announced a strategic collaboration with Bristol Myers Squibb to support their oncology drug portfolio. We also announced a strategic collaboration with Bristol Myers Squibb and Pathos to advance drug discovery in Alzheimer’s disease. Collectively, this makes BMS one of our largest data and modeling customers. Through this collaboration, BMS researchers will be able to train advanced AI models using de-identified data to surface breakthroughs and increase the probability of success when developing therapies for both cancer patients and those suffering from Alzheimer’s disease. Read on: https://lnkd.in/guWg_nZB & https://lnkd.in/gccNWKFS

Stop by Booths #1068 & 1069 to experience a live demo of Tempus Lens at #ESMO26. With Lens, quickly find, access, and analyze multimodal de-identified data records and uncover critical insights to accelerate research and innovation. Leverage our Al assistant, Tempus One, to quickly define detailed patient cohorts using natural language processing and transform complex criteria into actionable datasets in seconds. Explore unstructured clinical data and extract nuanced insights. See Lens in action: https://tempus.co/3TVB5CV

Tempus delivers insight generation at scale. Our comprehensive, AI-powered platform supports every stage of drug development—from discovery through commercialization. Heading to #ESMO26? Visit Booths #1068 & #1069 to connect with our team and explore our latest innovations. Learn more: https://tempus.co/4jFLmh3

Join us at #ESMO26 as we showcase novel clinical research revealing meaningful insights in cancer biology, treatment response, and patient outcomes. Visit us at booth #1068 & 1069 to experience live demos of our AI-powered technology and new product offerings designed to advance drug discovery and development. Learn more: https://tempus.co/4BeTOtI